Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma Meeting Abstract
| Authors: | Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; Sacco, J. J.; Shoushtari, A. N.; Orloff, M.; Carvajal, R. D.; Hamid, O.; Abdullah, S. E.; Holland, C.; Goodall, H.; Nathan, P.; Piperno-Neumann, S. |
| Abstract Title: | Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120605129 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.9527 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9527 -- Source: Wos |
